Insulet Corporation (PODD) experiences mixed results amid increasing competition and rising short interest. While some analysts maintain a buy rating on the stock, Citi flags competitive pressure as a potential risk. Following the announcement of a device correction, which results in a 19.3% development in short interest, Truist continues to hold on the buy recommendation. Despite weak share price momentum, analysts predict approximately 75% upside for the company. Amid the various challenges, Insulet appoints Mike Panos as the company's Chief Commercial Officer. The company also reports a rise in Q2 revenue by 32.9% and reaches a new 1-year low due to an analyst downgrade. However, the pressure increases as PODD faces a potential securities fraud lawsuit accusing the company of concealing device defects. Mixed views are seen with Insulet's Q1 2026 financial results announcement and the strategic expansion of the company. The company also initiates a voluntary medical device correction for certain Omnipod 5 Pods in the U.S, affecting its reputation.
